News from natera A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 03, 2019, 08:34 ET Data Presented at ASCO Shows Natera's Signatera Test Detects Immunotherapy Treatment Response in Metastatic Cancers

A new study demonstrates the ability of Natera's Signatera™ test to assess patient response to immunotherapy in the metastatic setting across...


May 21, 2019, 09:40 ET Noridian Posts Favorable Draft Local Coverage Determination for Natera's Prospera™ Kidney Transplant Test

Noridian, the Medicare Administrative Contractor (MAC) for California-based laboratories, has posted a favorable draft local coverage determination...


May 09, 2019, 12:04 ET New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier

A new clinical study shows that Natera's Signatera™ test identified colorectal cancer recurrence up to 16.5 months earlier than radiologic imaging by ...


May 07, 2019, 08:27 ET Signatera™ Blood Test Detects Bladder Cancer Relapse Up to Eight Months Earlier Than Current Clinical Standards

Natera, Inc. (NASDAQ: NTRA) today announced the publication of a clinical validation study demonstrating that its Signatera™ molecular residual...


May 06, 2019, 11:55 ET FDA Grants Breakthrough Device Designation to Natera's Signatera Test

Natera, Inc. (NASDAQ: NTRA) today announced that the U.S. Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its...


May 02, 2019, 20:51 ET Natera Announces First Quarter 2019 Earnings Conference Call

Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will...


Apr 17, 2019, 23:43 ET Natera Announces Pricing of Follow-On Offering

Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 5,263,158...


Apr 16, 2019, 16:12 ET Natera Launches Proposed Follow-On Offering

Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of...


Apr 16, 2019, 10:13 ET New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer

Natera, Inc. (NASDAQ: NTRA), Cancer Research UK, Imperial College London and the University of Leicester, today announced the publication of results...


Apr 10, 2019, 08:03 ET Natera Announces Plans to Commercialize Tumor Whole Exome Sequencing from Plasma

Natera, Inc. (NASDAQ: NTRA) Natera, a leader in cell-free DNA testing, today announced plans to commercialize a research-use-only (RUO) service for...


Mar 28, 2019, 12:46 ET Medicare Issues Draft Local Coverage Determination for Natera's New Prospera™ Kidney Transplant Rejection Test

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Palmetto MolDx has issued draft local coverage...


Mar 11, 2019, 06:03 ET Natera and BGI Genomics Announce $50M Partnership to Commercialize Signatera Oncology Test in China and to Develop Reproductive Health Tests in Select Markets on BGI's DNBseq™ Technology Platform

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA genetic testing, and BGI Genomics Co., Ltd., (300676.SZ), the largest cell-free DNA...


Jan 07, 2019, 08:03 ET Natera Announces Publication of Kidney Transplant Validation Study, Demonstrating Superior Data in Detection of Clinical and Subclinical Rejection

Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA, today announced clinical validation study results published in the Journal of Clinical...


Jan 04, 2019, 14:02 ET Natera To Webcast Live Presentation at the 37th Annual J.P. Morgan Healthcare Conference

Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, today announced that it will webcast a live...


Jan 04, 2019, 08:03 ET Natera Obtains Z-Codes for Signatera MRD and Treatment Monitoring Test in Oncology

Natera, Inc. (NASDAQ: NTRA), a global leader in non-invasive genetic testing and cell-free DNA, today announced the assignment of two Z-codes for the ...


Dec 06, 2018, 08:03 ET Natera Presents Breast Cancer Data at SABCS Showing Ability of Signatera (RUO) to Detect Molecular Residual Disease Up to Two Years Prior to Clinical Relapse and Predict Treatment Response

Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, presented data from two studies this week at ...


Nov 28, 2018, 08:03 ET Natera Receives Unique Z-Code for Its Kidney Transplant Rejection Monitoring Test

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the assignment of a unique Z-code for the company's kidney...


Sep 13, 2018, 13:02 ET Natera Signs Agreement with Bristol-Myers Squibb to Investigate Signatera™ ctDNA Assay as a Potential Biomarker for Opdivo (nivolumab) in a Prospective Phase 2 Adjuvant Non-Small Cell Lung Cancer Clinical Trial

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an agreement with Bristol-Myers Squibb to use Natera's...


Aug 02, 2018, 08:06 ET Study Shows Natera's Spectrum Preimplantation Genetic Testing for Aneuploidy Improves IVF Outcomes for All Women, Regardless of Maternal Age

Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced the publication of a study demonstrating the value of the...


Aug 01, 2018, 12:46 ET Natera, Inc. Announces Second Quarter 2018 Earnings Conference Call

Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will...


Jul 31, 2018, 11:00 ET Natera Appoints Roy Baynes to Board of Directors, Adding Deep Oncology Experience

Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing, has appointed Roy Baynes, MB.BCh., M.Med., PhD, FCP, FACP, Chief Medical Officer at...


Jul 12, 2018, 08:01 ET Natera Announces Pricing of Follow-On Offering

Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced the pricing of...


Jul 10, 2018, 16:05 ET Natera Launches Proposed Follow-On Offering

Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced the launch of a...


Jun 19, 2018, 08:03 ET Natera and Institut Jules Bordet Announce Collaboration in Neoadjuvant Breast Cancer

Natera, Inc., (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a research collaboration with the Institut Jules Bordet, an...


Jun 13, 2018, 08:03 ET Natera Announces New Clinical Utility Data and Issuance of CPT Code for NIPT in Twin Pregnancies

Natera (NASDAQ: NTRA), a leader in genetic testing and cell-free DNA analysis, announces that the American Medical Association has issued a new CPT...